Abstracts tagged "Axial spondyloarthritis and tumor necrosis factor (TNF)"

Abstract Number: 695 • 2018 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Inhibitor Persistence and Reasons for Discontinuation in US Veterans with Axial Spondyloarthritis
Delamo Bekele¹, Elizabeth Cheng², Christian Geier^3,4, Kavya Ganuthula⁵, Jessica Walsh^6,7, Maureen Dubreuil^8,9, Daniel O. Clegg¹⁰, Prashant Kaushik¹¹, Bernard Ng^12,13,14,15, Elizabeth Chang¹⁶, Andreas Reimold^17,18, Siba P. Raychaudhuri¹⁹, Ryan Duong²⁰, Kristine A Kuhn²¹, Yujin Park²² and Gail S. Kerr²³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, University of Colorado, Denver, CO, ³Rheumatology, Columbia University- NYP Hospital, New York, NY, ⁴Columbia University, New York, NY, ⁵Internal Medicine, VA Eastern Colorado Health Care System, Aurora, CO, ⁶Rheumatology Section, Salt Lake City Veterans Affairs, Salt Lake City, UT, ⁷Division of Rheumatology, Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT, ⁸Rheumatology, VA Boston Healthcare System & Boston University School of Medicine, Boston, MA, ⁹Rheumatology, VA Boston Healthcare System, Boston, MA, ¹⁰Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ¹¹Rheumatology/Medicine, Stratton VAMC, Albany, NY, ¹²Rheumatology, Seattle VAMC, Seattle, WA, ¹³Rheumatology, VA Puget Sound Healthcare System, Seattle, WA, ¹⁴Michael E. DeBakey VA Medical Center Health Services Research and Development Center of Excellence, Houston, TX, ¹⁵Division of Rheumatology, University of Washington, Seattle, WA, ¹⁶Rheumatology, Phoenix VAHCS, Phoenix, AZ, ¹⁷Rheumatology, Dallas VAMC, Dallas, TX, ¹⁸Rheumatology, Dallas VA Medical Center and University of Texas - Southwestern, Dallas, TX, ¹⁹Rheumatology, Sacramento VAMC, Mather, CA, ²⁰Rheumatology, Denver Veterans Affairs Medical Center and UC Denver SOM, Denver, CO, ²¹Division of Rheumatology, Rocky Mountain Regional Veterans Affairs Medical Center/University of Colorado School of Medicine, Aurora, CO, ²²Health Economics and Outcomes Research, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ²³Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC
Background/Purpose: Although tumor necrosis factor inhibitors (TNFi) have favorably altered the treatment landscape for patients with axial spondyloarthritis (AxSpA), permanent therapy is infrequent. Further, the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].